Release Date: July 2015Company Wide License (Global Site): USD 6,500
Number of Pages: 148
Number of Tables and Figures: 43
Synopsis: As a higher percentage of the global population lives longer, age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration are on the rise. In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.
Although surgery is the only option for the treatment of certain ophthalmic conditions such as cataracts, ophthalmic drugs continue to account for the highest percentage of spending within the wider market for ophthalmic products. Expected to surpass $20 Billion in global spending by the end of 2015, ophthalmic drugs remain the preferred approach to treat common eye disorders, ranging from dry eye syndrome to more complicated conditions such as glaucoma. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.
The “Ophthalmic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the ophthalmic drugs ecosystem including application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for ophthalmic drugs from 2015 through to 2030. The forecasts are segmented for over 5 therapeutic categories, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a sample of the report or any further inquiries please contact email@example.com
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
The report has the following key findings:
The report covers the following topics:
Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:The following companies and organizations have been reviewed, discussed or mentioned in the report:
Abbott Medical Optics
Bausch + Lomb
Cell Cure Neurosciences
FDA (Food and Drug Administration)
Merck and Co.
Roche Holding (F. Hoffmann-La Roche)
Santen Pharmaceutical Company
Valeant Pharmaceuticals International
Ventana Medical Systems